<DOC>
	<DOCNO>NCT01769469</DOCNO>
	<brief_summary>This prospective observational cohort sub-study subject enrol ATN 110 ATN 113 , prospective interventional trial .</brief_summary>
	<brief_title>Renal , Endocrine , Bone Changes Response FTC/TDF Uninfected Young Men Who Have Sex With Men ( YMSM ) .</brief_title>
	<detailed_description>This prospective observational cohort sub-study subject enrol ATN 110 ATN 113 study . All subject follow least 48 week . Subjects meet specific bone renal criterion Week 48 ATN 110 ATN 113 study follow additional 48 week Extension Phase ATN 110 ATN 113 ATN 117 . The maximum duration participation 96 week . There therapeutic intervention specific sub-study , extra study visit require participation sub-study . Questionnaires administer blood urine sample laboratory evaluation potential emtricitabine ( FTC ) /tenofovir ( TDF ) ( TruvadaÂ® ) toxicity obtain sub-study visit require ATN 110 ATN 113 study . Measurement bone mineral density ( BMD ) bone mineral content ( BMC ) dual-energy X-ray absorptiometry ( DXA ) scan plan part ATN 110 ATN 113 study , result utilize analysis study . This study require extra BMD BMC measurement .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Has enrol ATN 110 ATN 113 , Willing able provide write informed consent Subjects exempt undergoing DXA scan ATN 110 ATN 113 eligible enroll ATN 117 .</criteria>
	<gender>Male</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Tenofovir</keyword>
	<keyword>Emtricitabine</keyword>
	<keyword>Truvada</keyword>
	<keyword>Renal , endocrine , bone change</keyword>
	<keyword>HIV prevention</keyword>
	<keyword>PrEP</keyword>
</DOC>